

IPA Investigator Terms of Use

1. Scope

These Terms of Use («**Terms**») govern access to and use of IPA Investigator, an AI-enabled chatbot made available in connection with QIAGEN Ingenuity Pathway Analysis («**IPA**») by the QIAGEN entity identified as the contracting party under the applicable QIAGEN Digital Insights User Agreement governing IPA («**IPA EULA**») («**QIAGEN**», «**we**», «**us**»). IPA Investigator is available only to customers and users with valid IPA access for whom QIAGEN has enabled IPA Investigator. By accessing or using IPA Investigator, you accept these Terms.

These Terms supplement, and shall be read and applied together with, the IPA EULA to the fullest extent possible. The IPA EULA continues to apply to all matters not expressly regulated otherwise in these Terms, including confidentiality, audit rights, governing law and jurisdiction. In the event of a conflict relating to IPA Investigator, these Terms prevail to the extent of that conflict.

2. Permitted Use

You may use IPA Investigator solely for the purposes made available by QIAGEN in connection with IPA and only within the scope of your valid IPA access rights. IPA Investigator is intended to provide conversational assistance relating to IPA functionality, content, documentation, and outputs, as enabled by QIAGEN from time to time, to authorized IPA users who are qualified professionals, such as researchers, laboratory scientists, and other technical staff with relevant scientific training, and who are able to independently review and validate the information provided by IPA Investigator.

IPA Investigator is designed for informational, internal research and support purposes only. It is intended for Research Use Only and is not for use in diagnostic procedures. IPA Investigator does not provide professional, legal, medical, diagnostic, clinical, regulatory, financial or other expert advice and is not intended to replace independent scientific judgment, professional review, validation or decision-making. You acknowledge that IPA Investigator generates responses using artificial intelligence and may rely on IPA-related information, documentation, QIAGEN content, and other sources made available to it. IPA Investigator's responses or content may therefore be incomplete, inaccurate, outdated, unsuitable for a particular purpose or not applicable to your specific situation. You must independently verify any important information, analysis, interpretation, or recommendation before relying on it.

IPA Investigator's AI functionality is not intended to constitute a product, perform a safety-related function, or serve as a safety component of a product subject to European Union harmonization legislation. It is also not intended for any high-risk use case listed in Annex III of Regulation (EU) 2024/1689 (AI Act).

IPA Investigator is not designed or intended to process personal data, and we strongly discourage you from submitting personal data to IPA Investigator through queries or prompts. If you nonetheless include personal data in a query, it will be processed in accordance with our Privacy Notice.

You are solely responsible for ensuring that your use of IPA Investigator, and any information or content obtained through IPA Investigator, complies with all applicable laws and regulations, including, without limitation, data protection, intellectual property, healthcare, research integrity, and institutional compliance requirements and does not infringe upon the rights of third parties. IPA Investigator may use third-party technologies or services to support its functions, including Microsoft Azure OpenAI Service.

3. User Obligations

You agree not to:

- Use IPA Investigator to transmit or distribute unlawful, harmful, or malicious content;
- Interfere with or disrupt IPA Investigator or its security features;
- Attempt to gain unauthorized access to any part of IPA Investigator or its systems;

- Reverse engineer, decompile, disassemble, or otherwise attempt to discover the source code, underlying ideas, algorithms, or models of IPA Investigator, or permit others to do so;
- Use the IPA Investigator Materials or IPA Investigator output to create, train, or improve, directly or indirectly, any similar or competing product or service;
- Engage in any automated or systematic data gathering, scraping, or extraction of content from IPA Investigator;
- Remove, alter, or obscure any copyright, trademark or other proprietary notices contained in or on the IPA Investigator Materials or IPA Investigator output;
- Use automated tools to extract data without QIAGEN's express written permission;
- Share your login credentials or otherwise permit access to your individual account used for IPA Investigator to any third parties;
- Use IPA Investigator in any way other than as described in these Terms, nor for any purpose other than those described in Section 2.

Any of the above uses is strictly prohibited. QIAGEN reserves the right to restrict or terminate access to IPA Investigator in case of misuse, breach of these Terms or non-compliance with applicable law.

4. Registration and Account

Access to IPA Investigator requires a valid IPA account or other QIAGEN-enabled access method. Your credentials are personal and must be kept confidential. You are responsible for account activity, except to the extent caused by QIAGEN, and must promptly notify QIAGEN of suspected unauthorized access. Registration, authentication, and access management remain subject to the IPA EULA, the applicable ordering document, and any related account terms or documentation.

5. Intellectual Property

Any and all rights, title, and interest in and to IPA Investigator, including related content, data, software, algorithms, prompts, models, interfaces, documentation, know-how, and signs («**IPA Investigator Materials**»), are and shall remain the exclusive property of QIAGEN or its licensors. IPA Investigator Materials are protected by applicable intellectual property and other laws. Subject to your compliance with these Terms and the IPA EULA, QIAGEN grants you a limited, non-exclusive, non-transferable, non-sublicensable, and revocable right to access and use IPA Investigator solely for your internal research and informational purposes in connection with IPA and within the scope of your valid IPA access rights. This right applies only while IPA Investigator is enabled for the relevant IPA licensee and the applicable IPA EULA remains in effect. You are responsible for ensuring that you have all rights and permissions required to submit any prompts, queries, or other inputs to IPA Investigator. No rights, whether intellectual property or otherwise, are licensed, assigned, or transferred in connection with IPA Investigator except as expressly set forth in these Terms or the IPA EULA.

6. Data Protection and Privacy

We process personal data provided through or in connection with IPA Investigator in accordance with applicable data protection laws. You are not required to provide personal data in order to use IPA Investigator, and you must not submit personal data, patient-identifiable information, protected health information, human genetic information or other sensitive information to IPA Investigator.

IPA Investigator may process prompts, inputs, outputs, usage information, and technical data to provide, secure, monitor, support, and improve IPA Investigator and IPA. IPA Investigator is not intended to make decisions producing legal, medical, clinical, regulatory, or similarly significant effects on users solely on the basis of automated processing.

Further information about how QIAGEN collects and processes personal data, applicable user rights (including the rights of access, rectification, erasure, restriction, objection, portability, and withdrawal of consent), and the

use of cookies can be found in the IPA Investigator Privacy Notice, which is available here: <https://www.qiagen.com/resources/downloadfiles/ipa-investigator-agent-privacy-notice> and our general Privacy Policy available at <https://www.qiagen.com/us/privacy/privacy-policy>.

7. Limitation of Liability and Warranty

To the fullest extent permitted by applicable laws, IPA Investigator is provided «as is» and «as available». No specific availability, uptime, or service levels are guaranteed. QIAGEN makes no warranties, express or implied, regarding the accuracy, reliability, fitness for purpose, merchantability, or non-infringement of IPA Investigator or its outputs. QIAGEN shall not be liable in any way for any interruption of access, system overload, network issues, maintenance, suspension, or discontinuation of IPA Investigator, or for damages of any kind resulting therefrom, except to the extent liability cannot be excluded or limited under mandatory applicable law. In particular, technical problems or maintenance work may result in interruption of access to or suspension of IPA Investigator, for which QIAGEN shall not be liable to pay any compensation. To the extent permitted by applicable law, QIAGEN excludes all liability for direct, indirect, or consequential damages arising from your use of or inability to use IPA Investigator. You use IPA Investigator at your own risk.

8. Indemnification

You agree to indemnify, defend, and hold harmless QIAGEN from any claims, damages, or expenses arising from your use of IPA Investigator, your violation of these Terms, or your infringement of any third-party rights.

9. Changes to the Terms

We reserve the right to amend any section of these Terms at any time. Changes will be communicated via IPA Investigator or other appropriate means. Continued use of IPA Investigator after such changes constitutes your acceptance of the new Terms.

10. Modification of IPA Investigator and Termination

We may suspend or modify IPA Investigator and its services at any time, without prior notice. We may also suspend or terminate your access to IPA Investigator, at any time, with or without notice, if you breach these Terms or if required by law. Upon termination, your right to use IPA Investigator ceases immediately.

11. Severability

If any provision of these Terms is found to be invalid or unenforceable, the remaining provisions shall remain in full force and effect.

Last updated: [27.07.2026]